Клиническое значение дисфункции эндотелия при артериальной гипертонии

1. Малая Л.Т., Корж А. Н., Балковая Л. Б. Эндотелиальная дисфункция при патологии сердечно-сосудистой системы. Харьков: ТОРСИНГ, 2000; с. 10–20.
2. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. New Engl J Med 1990; 323: 27–36.
3. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373–6.
4. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–6.
5. Ignarro LJ. Wei Lun Visiting Professorial Lecture: Nitric oxide in the regulation of vascular function: an historical overview. J Card Surg 2002 Jul-Aug; 17 (4): 301–6.
6. Schiffrin EL, Hayoz D. Angiotension II Receptor antagonists. Edited by Murray Epstein and Hans R. Brunner. Hanley Belfus, INC Philadelphia. 2001; 279–89.
7. Taddei S, Virdis A, Chiadoni L, Salvetti A. The pivotal role of endotelium in hypertension. Medicographia. Issue 59. 1999; 21 (1): 22–9.
8. Stroes ES, Koomans НА, de Bmin TW, Rabelink ТJ. Vascular function in the forearm of hypercholesterolaemic patients off and оn lipid-lowering medication. Lancet 1995; 346: 467–71.
9. Johnstone МТ, Creager SL, Scales KM et al. Impaired endothelium-dependent vasodilation in patients with insulindependent diabetes mellitus. Circulation 1993; 88: 2510–6.
10. Zeiher АM, Schachinger V, Мinnenf. Long-term cigarette smoking impairs endothelium independent coronary arterial vasodilator function. Circulation 1995; 92: 1094–100.
11. Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodelling of hypertension. Hypertension. 1991; 18 (suppl. III): III–115–III–121.
12. Taddei S, Virdis A, Ghiadoni L, Salvetti A. The role of endothelium in human hypertension. Curr Opin Nephrol Hypertension 1998; 7 (2): 203–9.
13. Mattel P, Virdis A, Ghiadoni L, Taddei S, Salvetti A. Endothelial function in hypertension. J Nephrol 1997; 10 (4): 192–7.
14. Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997; 20 (5): 426–32.
15. Volker Schachinger MD; Martina B.Britten; Andreas M. Zeither. Prognostic impact of coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease. Circulation 2000; 101: 1899–906.
16. Haeffliger IO, Meyer P, Flammer J, Luscher TF. The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv Ophthalmol 1994; 39 (2): 123–32.
17. Stehouwer CD, Jager A, Donker AJ. Microalbuminuria in essential hypertension: of limited value as an indicator of patients with a high risk for complications. Ned Tijdschr Geneeskd 1997; 141 (34): 1649–53.
18. Pepine CJ, Celermajer DS, Drexler H. Vascular health as a therapeutic target in cardiovascular disease. University of Florida 1998.
19. Schretzenmayr A. Uber kreislaufregulatorische vorgange an den groben arterien bei muskelarbeit. Pflugers. Arch Ges Physiol 1933; 232: 743–8.
20. Pohl U, Holtz J, Busse R et al. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986; 8 (1): 37–44.
21. Cooke JP, Rossitch E, Andon N et al. Flow activates endothelial potassium channel to release endogenous nitrovasodilator. Clin Invest 1991; 88: 1663–71.
22. Celermajer DS, Sorensen KE, Gooch VM et al. Non – invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5.
23. Blann AD, Tarberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Brit J Haematol 1995; 90: 244–8.
24. Moshage H, Kok B, Huzenga R et all. Nitrite and nitrate determination in plasma: A critical evaluation. Clin Chem 1995; 41: 892–6.
25. Deanfield J, Donald A, Ferri C, Giannattasio C et al. Endothelial function and dysfunction. Part I: Methodological issues foe assessment in the different vascular beds: A statement by the Working group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertes 2005 Jan; 23 (1): 7–17.
26. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar hemodynamic properties in hypertensive patients. Blood pressure Suppl. 2004 Oct; 1: 17–32
27. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: ИД "Медиа Медика", 2004.
28. Ярик-Мартынова И.Р., Шестакова М.В., Александров А.А., Ахматова Ф.Д. Влияние β-блокатора небиволола на тонус симпатической нервной системы и микроальбуминурию у больных сахарным диабетом 1 типа. Тезисы докладов 3 Российского Диабетологического Конгресса. М., 2004.
29. Zhang X, Kichuk MR, Mital S et al. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am J Cardiol 1999; 84: 27L–33L.
30. Yang Z, Bauer E, von Segesser L et al. Different mobilization of calcium in endothelin-1 – induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol 1990; 88: 832–6.
31. Effect of nifedipine and cerivastatine on coronary endothelial function in patients with coronary artery disease. The ENCORE I Study. (Evaluation of Nifedipine and Cerivaststine On Recovery of coronary Endothelial Function). Circulation 2003; 107: 422–8.
32. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifediine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
33. Simon A, Gariepy J, Moyse B, Levenson J. Differential effect of nifedipine and co-amilozide on the progression of early carotid wall changes.Circulation 2001; 103 (24): 2949.
34. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410.
35. Poole-Wilson PA, Lubsen J, Kirwan BA et al. on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–57.

Д.В.Небиеридзе

ГНИЦ профилактической медицины, Москва